度普利尤单抗改善儿童特应性皮炎线性生长与骨生物标志物
这项3期随机安慰剂对照试验及其开放标签延伸研究纳入6至11岁重度特应性皮炎患儿,先接受度普利尤单抗或安慰剂治疗16周,随后开放标签至52周。结果显示度普利尤单抗组身高百分位增长和骨碱性磷酸酶水平改善优于安慰剂,且第16周转入度普利尤单抗者至52周改善与持续用药者相当。
要点
- 重度特应性皮炎患儿基线身高百分位偏低者比例较高。
- 度普利尤单抗组第16周31.3%患儿身高百分位增≥5,优于安慰剂组15.5%。
- 骨碱性磷酸酶水平在正常范围内,度普利尤单抗组显著高于安慰剂组并持续至52周。
核心结论
- 度普利尤单抗治疗儿童特应性皮炎与身高和骨碱性磷酸酶水平改善相关。
研究设计与样本
- 3期随机安慰剂对照试验:6至11岁重度特应性皮炎患儿接受度普利尤单抗或安慰剂16周。
- 随后开放标签延伸至52周,第16周转入度普利尤单抗。
主要发现
- 基线时重度特应性皮炎患儿在较低身高百分位中占比过高。
- 基线身高百分位低于40的度普利尤单抗组患儿中,31.3%第16周身高百分位增≥5,安慰剂组为15.5%(P < .05)。
- 同一亚组第52周有50.7%患儿身高百分位增≥5。
- 骨碱性磷酸酶水平全程在正常范围内,第16周度普利尤单抗组显著高于安慰剂组,并进一步增至第52周。
- 第52周时,第16周转入度普利尤单抗者的身高和骨碱性磷酸酶改善与全程用药者相当。
关键数值与推荐
- 身高百分位增≥5的比例:度普利尤单抗组31.3% vs 安慰剂组15.5%(P < .05),对象为基线身高百分位低于40的患儿,时间点为第16周。
- 第52周同一亚组身高百分位增≥5的比例为50.7%。
- 骨碱性磷酸酶水平全程在正常范围内,度普利尤单抗组第16周显著高于安慰剂组。
临床怎么用
- 对重度特应性皮炎患儿,度普利尤单抗治疗可能有利于身高增长和骨代谢改善。
- 治疗期间可关注身高百分位和骨碱性磷酸酶水平变化。
局限性
- 研究持续时间仅1年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Moderate and severe atopic dermatitis (AD) may affect bone growth and mineral density in children. OBJECTIVE: To investigate stature, height gain, and biomarker of mineralization bone alkaline phosphatase (BALP) level over time in children with AD treated with dupilumab. METHODS: Children aged 6 to 11 years with severe AD received dupilumab or placebo in a phase 3 trial for 16 weeks, followed by dupilumab in an open-label trial to week 52. Endpoints included baseline height percentile distribution, proportion of patients achieving ≥5-percentile height increase at weeks 16 and 52, and BALP level to week 52. RESULTS: Children with severe AD were overrepresented in lower height percentiles at baseline. Among dupilumab-treated children below the 40th height percentile at baseline, 31.3% achieved ≥5-percentile height increase (vs 15.5% with placebo, P < .05) at week 16, and 50.7% at week 52. BALP level, while within normal range throughout, was significantly higher with dupilumab vs placebo at week 16, with further increase to week 52. At week 52, patients who transitioned to dupilumab at week 16 attained height and BALP improvements comparable with patients receiving dupilumab throughout. LIMITATIONS: One-year duration. CONCLUSION: Dupilumab treatment in children with AD was associated with height and BALP level improvements.
引用
- Irvine AD, Paller AS, Siegfried EC, et al. Dupilumab treatment improves linear growth and bone biomarkers in children with atopic dermatitis: Post hoc analysis of a phase 3 randomized, placebo-controlled clinical trial and an open-label extension study. J Am Acad Dermatol. 2026. PMID: 42413781. doi:10.1016/j.jaad.2026.07.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。